Filtered By:
Drug: Temodar
Procedure: MRI Scan
This page shows you your search results in order of date.
Order by Relevance | Date
Total 20 results found since Jan 2013.
Clinical decision-making based on 11C-methionine PET in recurrent Cushing's disease with equivocal MRI findings
CONCLUSIONS: MET-PET is extremely useful for confirming equivocal lesions on MRI in patients with recurrent CD and for deciding further treatment options. The authors propose a novel protocol based on MET-PET results for treating patients with relapsing CD in whom the recurrent tumors cannot be confirmed with MRI.PMID:37410630 | DOI:10.3171/2023.5.JNS23179
Source: Journal of Neurosurgery - July 6, 2023 Category: Neurosurgery Authors: Atsushi Ishida Koichiro Kaneko Ryogo Minamimoto Masatoshi Hotta Naoko Inoshita Koji Takano Shozo Yamada Source Type: research
Imaging Findings of < sup > 18 < /sup > F-Choline and < sup > 18 < /sup > F-DOPA PET/MRI in a Case of Glioblastoma Multiforme Pseudoprogression: Correlation with Clinical Outcome
We describe the case of 74-year-old-male, previously treated with fronto-parietal craniotomy due to primary glioblastoma multiforme (GBM), followed by concurrent radiation therapy (RT) and temozolomide (TMZ) chemotherapy. Magnetic resonance imaging (MRI) of the brain, at 1 month after completing RT + TMZ, depicted partial response. Three months later, the patient was submitted to a further brain MRI, that resulted doubtful for therapy induced changes (i.e., pseudoprogression). The patient, who had been previously treated with prostatectomy for prostate cancer (PC), underwent a positron emission tomography/computed tomograp...
Source: Molecular Medicine - October 31, 2022 Category: Molecular Biology Authors: Luca Filippi Angela Spanu Oreste Bagni Orazio Schillaci Barbara Palumbo Source Type: research
Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature
CONCLUSIONS: Regorafenib was certainly a first turning point in the second-line treatment of GBM, showing longer response rates and mostly disease stability than bevacizumab. A switch-maintenance strategy with tyrosine kinase inhibitors may represent a valid second-line therapeutic option.PMID:35916797 | DOI:10.26355/eurrev_202207_29287
Source: Pharmacological Reviews - August 2, 2022 Category: Drugs & Pharmacology Authors: M De Felice P De Marinis G Martin S Bruscella A De Bellis L Poliero G Turitto Source Type: research
Intratumoral oncolytic herpes virus G47 ∆ for residual or recurrent glioblastoma: a phase 2 trial
This study showed a survival benefit and good safety profile, which led to the approval of G47∆ as the first oncolytic virus product in Japan.PMID:35864254 | DOI:10.1038/s41591-022-01897-x
Source: Herpes - July 21, 2022 Category: Infectious Diseases Authors: Tomoki Todo Hirotaka Ito Yasushi Ino Hiroshi Ohtsu Yasunori Ota Junji Shibahara Minoru Tanaka Source Type: research
An aggressive lactotroph pituitary tumor in a young male: A pituitary carcinoma without metastasis
Clin Neuropathol. 2022 May 16. doi: 10.5414/NP301458. Online ahead of print.ABSTRACTThis case report concerns a 31-year-old male with an aggressive pituitary tumor who presented initially with bitemporal hemianopsia and slightly elevated prolactin. On magnetic resonance imaging of the brain, there was a sellar mass with parasellar invasion to the lateral aspects of the internal carotid arteries, compressing the optic chiasm. On histopathological analysis, the diagnosis was made of a densely granulated lactotroph pituitary tumor with a Ki67 proliferation rate of 15%, a mitotic count of 6/10 high-power fields, and p53 positi...
Source: Clinical Neuropathology - May 16, 2022 Category: Pathology Authors: Friederike E Roelandt-Schumann Rob A Vergeer Astrid G W Korsten-Meijer Miranda C A Kramer Henri ëtte E Westerlaan Jan W R Pott Janine Nuver Gerrit van den Berg Wilfred F A den Dunnen Source Type: research
